Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver – Will it hit the moving target?

Abstract

Insulin-like growth factor 1 receptor (IGF-1R) inhibitors have anti-tumor activity in various cancers. The development of IGF-1R inhibitors is a multi-dimensional and complex issue, involving many different drugs, and affecting several different points along the pathway. Matching patients with these agents based on molecular profiling/signatures will be essential for the proper development of this type of targeted agent.

Keywords:

• clinical trials
• insulin-like growth factor 1 receptor
• monoclonal antibody
• Phase I clinical trials
• resistance pathway
• response signature
• targeted therapy

Acknowledgment

V Subbiah and LS Angelo contributed equally.

Notes